<th id="grzca"></th>
<b id="grzca"><menuitem id="grzca"></menuitem></b>

<th id="grzca"></th>
<strong id="grzca"><form id="grzca"></form></strong>
  • <del id="grzca"><form id="grzca"></form></del>

    全國服務(wù)咨詢熱線:

    18438616290

    Products產(chǎn)品中心
    首頁 > 產(chǎn)品中心 > 生化試劑 > 小分子化合物 > abs47027316Diflunisal 22494-42-4

    Diflunisal 22494-42-4

    簡要描述:Diflunisal 22494-42-4
    Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs.

    • 產(chǎn)品型號:abs47027316
    • 廠商性質(zhì):生產(chǎn)廠家
    • 更新時間:2025-12-05
    • 訪  問  量:740

    詳細(xì)介紹

    品牌absinCAS22494-42-4
    分子式C13H8F2O純度>98%
    分子量250.2貨號abs47027316
    規(guī)格25mg供貨周期現(xiàn)貨
    主要用途used to relieve pain accompanied with in應(yīng)用領(lǐng)域化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合

    Diflunisal 22494-42-4

    產(chǎn)品描述
    描述

    Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis. .

    純度
    >98%
    儲存/保存方法
    Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
    基本信息
    別名
    二氟ni柳;二氟苯水楊酸;MK-647
    外觀
    白色粉末
    可溶性/溶解性
    DMSO : 50 mg/mL (199.84 mM; Need ultrasonic)

    Ethanol : 20 mg/mL (79.94 mM)
    生物活性
    靶點
    COX ,p300
    In vitro(體外研究)
    Diflunisal, an FDA-approved drug containing a salicylic acid substructure, inhibited CBP/p300 more potently than salicylate. Diflunisal exhibits anti-tumor activity against a specific leukemia carrying a t(8;21) translocation, a tumor previously reported to be dependent on p300 in vitro and in vivo.
    In vivo(體內(nèi)研究)
    Diflunisal-mediated kinetic stabilization of TTR(Rate-limiting transthyretin) should ameliorate TTR amyloidoses, provided that the nonsteroidal anti-inflammatory drug liabilities can be managed clinically.
    參考文獻(xiàn)
    參考文獻(xiàn)
    • 1. Jeske AH. J Gt Houst Dent Soc. 1999, 71(4):39-40.

    • 2. Mao H, et al. J Am Chem Soc. 2001, 123(43):10429-35.

    • 3. Moore PA, Hersh EV. J Am Dent Assoc. 2001, 132(4):451-6.

    研究領(lǐng)域
    研究領(lǐng)域
    Immunology
    CancerTumor biomarkers
    CancerTumor immunology
    Drug DiscoverySmall Molecule DrugLead Compound Discovery
    Diflunisal 22494-42-4溫馨提示:本產(chǎn)品僅作科研實驗使用,不支持臨床等研究

    產(chǎn)品咨詢

    留言框

    • 產(chǎn)品:

    • 您的單位:

    • 您的姓名:

    • 聯(lián)系電話:

    • 常用郵箱:

    • 省份:

    • 詳細(xì)地址:

    • 補(bǔ)充說明:

    • 驗證碼:

      請輸入計算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7
    愛必信(上海)生物科技有限公司
    地址:上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
    傳真:
    關(guān)注我們
    歡迎您關(guān)注我們的微信公眾號了解更多信息:
    歡迎您關(guān)注我們的微信公眾號
    了解更多信息
    <th id="grzca"></th>
    <b id="grzca"><menuitem id="grzca"></menuitem></b>

    <th id="grzca"></th>
    <strong id="grzca"><form id="grzca"></form></strong>
  • <del id="grzca"><form id="grzca"></form></del>

    丰满人妻一区=区三区在线视频53 狠狠狠狠狠狠狠狠狠狠狠狠狠狠狠狠 | 亚洲欧洲在线视频 | 黄色成人在线 | 欧美三级片视频在线播放 | 三级在线观看视频 |